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Inactivation of peptidylglycine α-hydroxylating monooxygenase 
by cinnamic acid analogs
Neil R. McIntyre1, Edward W. Lowe Jr1,*, Matthew R. Battistini2, James W. Leahy2,3, and 
David J. Merkler2
1Department of Chemistry, Xavier University of Louisiana, New Orleans, LA, USA
2Department of Chemistry, University of South Florida, Tampa, FL, USA
3Florida Center for Drug Discovery and Innovation, Tampa, FL, USA
Abstract
Peptidylglycine α-amidating monooxygenase (PAM) is a bifunctional enzyme that catalyzes the 
final reaction in the maturation of α-amidated peptide hormones. Peptidylglycine α-hydroxylating 
monooxygenase (PHM) is the PAM domain responsible for the copper-, ascorbate- and O2-
dependent hydroxylation of a glycine-extended peptide. Peptidylamidoglycolate lyase is the PAM 
domain responsible for the Zn(II)-dependent dealkylation of the α-hydroxyglycine-containing 
precursor to the final α-amidated peptide. We report herein that cinnamic acid and cinnamic acid 
analogs are inhibitors or inactivators of PHM. The inactivation chemistry exhibited by the 
cinnamates exhibits all the attributes of a suicide-substrate. However, we find no evidence for the 
formation of an irreversible linkage between cinnamate and PHM in the inactivated enzyme. Our 
data support the reversible formation of a Michael adduct between an active site nucleophile and 
cinnamate that leads to inactive enzyme. Our data are of significance given that cinnamates are 
found in foods, perfumes, cosmetics and pharmaceuticals.
Keywords
Cinnamate; cinnamate—Cu(I) complex; peptidylglycine α-hydroxylating monooxygenase; time-
dependent enzyme inactivation
Introduction
Peptidylglycine α-hydroxylating monooxygenase (PHM) is a copper-, O2- and ascorbate-
dependent enzyme responsible for the oxidative cleavage of C-terminal glycine-extended 
precursor peptides to the active α-amidated peptide and glyoxylate1,2. This reaction 
proceeds by the abstraction of hydrogen from the glycyl Cα followed by the O2-dependent 
Address for correspondence: David J. Merkler, Department of Chemistry, University of South Florida, 4202 E. Fowler Avenue, CHE 
205, Tampa, FL 33620-5250, USA. Tel: +1 8139743579. Fax: +1 8139743203. merkler@usf.edu.
*Present address: Vanderbilt University Center for Structural Biology, 465 21st Avenue South, BIOSCI/MRBIII, Room 5144A, 
Nashville, TN 37232-8725, USA.
Declaration of interest
The contents are solely the responsibility of the authors and do not necessarily represent the official views of the Louisiana Cancer 
Research Consortium or the National Institutes of Health.
HHS Public Access
Author manuscript
J Enzyme Inhib Med Chem. Author manuscript; available in PMC 2017 August 01.
Published in final edited form as:
J Enzyme Inhib Med Chem. 2016 August ; 31(4): 551–562. doi:10.3109/14756366.2015.1046064.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
hydroxylation to generate a C-terminal α-hydroxyglycine-extended peptide3,4. Dealkylation 
of the α-hydroxyglycine-extended peptides is catalyzed by peptidylamidoglycolate lyase 
(PAL), a zinc- and calcium-dependent enzyme (Figure 1)4–6. The relationship between PHM 
and PAL is complex and species-dependent. Vertebrates produce a bifunctional protein, 
referred to as peptidylglycine α-amidating mono-oxygenase (PAM), which contains one 
PHM and one PAL7, while invertebrates generate the monofunctional PHM and PAL 
enzymes from separate genes8–10. Bifunctional and pentafunctional (four PHM to one PAL) 
enzymes are reported from different mollusk species11,12. Furthermore, alternative splicing 
of the PAM mRNA and proteolytic processing of the multifunctional PAM proteins results in 
a diverse array of catalytically active forms of PAM, PHM, and PAL in vivo13,14. The 
significance of the complexities within the PAM/PHM/PAL system is currently unclear, but 
hints at a regulatory strategy for the production of α-amidated peptides or toward a 
biological function for C-terminal α-hydroxylated peptides.
In mammals, PAM activity has been found in the blood and in many tissues15, with the 
highest levels being found in pituitary, central nervous system and the atrium of the 
heart7,14–16. A large percentage of mammalian bioactive peptides, ~50%, possess an α-
amidated C-terminus. As a consequence, a number of pathological conditions correlate to 
dysfunction in the expression of specific α-amidated peptides or one of the PAM/PHM/PAL 
proteins, including cancer17,18, arthritis19, inflammation20,21 and Alzheimer’s disease22. 
Peptide amidation is important in insects as well because ≥80% of all insect bioactive 
peptides are α-amidated23. Considerable effort has been expended to develop 
PAM/PHM/PAL inhibitors as such compounds could prove valuable as either insecticides or 
drugs to treat diseases related to imbalances in α-amidated peptide production24–37. 
Included amongst these works are reports that cinnamates and ring-substituted cinnamates 
are irreversible inactivators of PHM32,33. Intriguingly, Bradbury et al.33 suggest that 
cinnamate-mediated inactivation of PHM results from the formation of a vinyl radical 
(Figure 1). This chemistry is related to the irreversible inactivation of PHM by trans-
benzoylacrylate25, trans-4-phenyl-3-butenoate (PBA, also known as trans-styrylacetate)36,37, 
and trans-styrylthioacetate38; PBA inactivation is proposed to occur via the formation of an 
allylic radical (Figure 1)35,37. The formation of vinyl radical during the cinnamate-mediated 
inactivation of PHM is mechanistically relevant because this would require the formation of 
a PAM-based oxidant that is sufficiently strong to abstract a hydrogen atom from the α-
carbon of cinnamate. If true, this may force a revision of the current models for PHM 
catalysis39–42.
In addition to the potential mechanistic significance of the cinnamate-mediated inactivation 
of PHM, man has a long history of the exposure to and uses for cinnamate and cinnamate 
derivatives. Cinnamates are found in fruits, fruit juices, vegetables and flowers and are used 
in perfumes, cosmetics and pharmaceuticals43–46. Medically, cinnamates are known to lower 
blood glucose levels47 and have potential as treatments for cancer, tuberculosis and other 
human diseases48,49. The inactivation of PHM by cinnamate merits further investigation 
given the important role of the PAM/PHM/PAL system in the biosynthesis of α-amidated 
peptide hormones1,2. Herein, we report that cinnamate and a number of cinnamate analogs 
are PHM inhibitors, information that contributes toward the rational design of PHM-directed 
therapeutics. A subset of these compounds, cinnamate and three ring-substituted cinnamates, 
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are also turnover-dependent inactivators of PHM. We find that inactivated PHM is 
indistinguishable from untreated enzyme and find no evidence for cinnamate oxidation 
during the inactivation reaction. The reversible Michael addition of an active site nucleophile 
to cinnamate could account for our data and may explain the inactivation of PHM by a 
variety of acrylates20,30,35, and the 2- and 3-alkenoates32 as well as provide an explanation 
for the lack of PHM-labeling by 3H-PBA37.
Materials and methods
Chemicals and instrumentation
Cinnamic acid, 2-trifluorocinnamic acid, 3-(3-pyridyl)acrylic acid, phenylpropiolic acid, 
3,4-methylenedioxycinnamic acid, N,N-dimethylaminocinnamic acid, urocanic acid, 4-
aminocin-namic acid and perdeuterated cinnamic acid (C6D5–CD=CD–COOH) were from 
Sigma (St. Louis, MO); bovine catalase was from Worthington (Lakewood, NJ); and 
[ring-14C6]-trans-cinnamic acid (specific activity of 50–60 mCi/mmol and 0.1 mCi/mL) was 
from American Radiolabeled Chemicals (St. Louis, MO). Recombinant rat bifunctional 
PAM was a gift from Unigene Laboratories, Inc. (Fairfield, NJ), was greater than 95% pure 
as judged by SDS polyacrylamide electrophoresis (Figure S1, Supplementary material) and 
had a specific activity of ≥4.0 μmol of O2 consumed/min/mg at 37°C under standard assay 
conditions50. All other reagents were of the highest quality commercially available.
Oxygen consumption was monitored using a Yellow Springs Instrument Model 5300 
(Yellow Springs, OH) oxygen monitor. Spectrophotometric studies were performed on a 
JASCO UV-VIS spectrophotometer (Easton, MD). HPLC separations were performed on an 
Agilent HP 1100 (Santa Clara, CA), equipped with a four-channel solvent mixing system, a 
quaternary pump and either a variable wavelength UV detector or a Gilson Model 121 
fluorimeter.
Synthesis of N-dansyl-4-aminocinnamic acid
A solution of dansyl chloride (400 mg, 1.5 mmol) in a minimal volume of dry pyridine (~2 
mL) was added dropwise to a N2-purged solution of 4-aminocinnamic acid (500 mg, 3.1 
mmol) in 50 mL of dry pyridine at 60°C. After 24 h, the reaction was diluted and extracted 
with Et2O (100 mL × 3), yielding a yellow oil upon concentration. Crystallization of the 
final N-dansyl-4-aminocinnamic acid was performed with methanol/H2O (285 mg, 
48%). 1H NMR (400 MHz, CDCl3): δ 8.68 (s, 2H), 8.50 (d, J = 8.5 Hz, 3H), 8.31 (d, J = 8.5 
Hz, 3H), 8.23 (d, J = 7.4 Hz, 3H), 7.86–7.81 (m, 1H), 7.63–7.53 (m, 7H), 7.48–7.37 (m, 
7H), 7.30 (d, J = 8.6 Hz, 7H), 7.17 (d, J = 7.6 Hz, 3H), 6.99 (d, J = 8.6 Hz, 6H), 6.25 (d, J = 
16.0 Hz, 3H), 2.85 (s, 21H). m/z observed: 397.1. The 1H NMR spectrum of N-dansyl-4-
aminocinnamic acid is included in the Supplementary materials (Figure S2, Supplementary 
materials).
Measurement of the PHM-dependent consumption of O2
Enzyme concentrations were determined by the Bradford method using bovine serum 
albumin as a standard51. The enzymatic reactions were initiated by the addition of PAM (0.5 
nmol, 35 μg) into 2.0 mL of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 
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0.001% (v/v) Triton X-100, 10 μg/mL bovine catalase, 1.0 μM Cu(NO3)2, 5.0 mM sodium 
ascorbate at 37.0 ± 0.1°C. N-Acetylglycine (8 mM) served as the oxidizable substrate for the 
inhibition studies45. Initial rates were measured by following the PAM-dependent 
consumption of O2 using an oxygen electrode. All kinetic data were determined in duplicate 
and are reported as mean ± standard deviation.
PHM inhibition
The initial rates of O2 consumption by PHM were measured at eight different concentrations 
of the oxidizable substrate in the absence and presence of three different inhibitor 
concentrations. N-Acetylglycine served as the oxidizable substrate at concentrations of 1.0–
45.0 mM. The initial velocities from the inhibition experiments were fit to the equations for 
competitive, noncompetitive and uncompetitive inhibition, respectively, using SigmaPlot 9.0 
(Systat Software, San Jose, CA). All the inhibition data contained herein were the best fit to 
the one-site competitive inhibition model for the calculation of KI,obs.
PHM inactivation
Reactions consisting of 100 μL containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% 
(v/v) ethanol, 0.001% (v/v) Triton X-100, 10 μg/ml bovine catalase, 1.0 μM Cu(NO3)2, 5.0 
mM sodium ascorbate and the desired concentration of the inactivator were initiated by the 
addition of 1.0 nmol (70 μg) enzyme and incubated at 37°C. Aliquots of 15 μL were 
withdrawn at various intervals and diluted into 2.0 mL reactions containing 100 mM MES/
NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 μg/mL 
bovine catalase, 1.0 μM Cu(NO3)2, 5.0 mM sodium ascorbate, and 20 mM N-acetylglycine 
and monitored for O2 consumption. The inactivator concentrations employed were based on 
their respective KI,obs values that had been determined in separate experiments.
PAL inactivation
Inactivation of PAL activity within bifunctional PAM was evaluated by measuring the initial 
rates of glyoxylate formation from α-hydroxyhippurate. Reactions of 0.3 nmol (20 μg) of 
PAM in a 100 μL solution containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% 
(v/v) ethanol, 0.001% (v/v) Triton X-100, and a concentration of cinnamate or analog equal 
to 5 × IC50 were incubated for 2 h. A 20 μL aliquot was removed and used to initiate a 1.0 
mL reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 
0.001% (v/v) Triton X-100, and 10 mM α-hydroxyhippurate. At 10 min intervals from 10 to 
60 min, a 100 μL aliquot was removed, added to a vial containing 20 μL of 6% (v/v) 
trifluoroacetic acid (TFA) to terminate the reaction, and the concentration of glyoxylate 
measured in the acidified samples.
Glyoxylate was determined by the spectrophotometric method of Christman et al.52 as 
modified by Katopodis and May25. Standard curves of [glyoxylate] versus A520 were 
constructed in the appropriate buffers using a glyoxylate solution that had been calibrated by 
measuring the glyoxylate-dependent oxidation of NADH (Δε340 = 6.22 × 103 M−1 cm−1) as 
catalyzed by lactate dehydrogenase.
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Tiopronin protection against the cinnamate-mediated inactivation of PHM
Protection of PHM against the cinnamate-mediated inactivation by tiopronin was evaluated 
by comparing the rate of glyoxylate formation from N-acetylglycine in the absence of 
cinnamate (no inactivator control), in the presence of cinnamate, and in the presence of 
cinnamate and tiopronin. Reactions of 0.3 nmol (20 μg) of PAM in a 100 μL solution 
containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) 
Triton X-100, 0 or 7.5 mM cinnamate, and 0 or 60 μM tiopronin were incubated for 2 h. A 
20 μL aliquot was removed and used to initiate a 1.0 mL reaction containing 100 mM MES/
NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 μg/mL 
bovine catalase, 1.0 μM Cu(NO3)2, 5.0 mM sodium ascorbate and 8 mM N-acetylglycine 
and monitored for glyoxylate production. At 10 min intervals from 10 to 90 min, a 100 μL 
aliquot was removed, added to a vial containing 20 μL of 6% (v/v) TFA to terminate the 
reaction, and the concentration of glyoxylate measured in the acidified samples as described 
above.
Reversibility of inactivation
To investigate the reversibility of inactivation, a reaction mixture of 250 μL containing 100 
mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 
μg/mL bovine catalase, 1.0 μM Cu(NO3)2, 5.0 mM sodium ascorbate and 7 mM cinnamate 
(2 × KI,obs) was initiated by the addition of enzyme and incubated at 37 °C for 2 h. The 
reaction was then extensively dialyzed and concentrated to 50 μL. The concentrated, 
cinnamate-treated enzyme was then used to initiate a 1.0 mL reaction containing 100 mM 
MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100 and 10 
mM hippurate. At various time intervals, the recovery of PHM activity was tested after 
quenching a 100 μL aliquot with 1% (v/v) TFA. The concentration of glyoxylate produced in 
the acidified samples was used to test for PHM reactivation.
Investigation of enzyme modification by the cinnamates
Covalent modification of PAM was investigated using N-dansyl-4-aminocinnamate, a 
fluorescent molecule, as an inactivator. A reaction (0.5 mL) containing 100 M MES/NaOH 
pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 μg/mL bovine 
catalase, 1.0 μM Cu(NO3)2, 5.0 mM sodium ascorbate and 1.0 mM N-dansyl-4-
aminocinnamate was initiated by the addition of 0.7 nmol (50 μg) of enzyme and incubated 
at 37° C for 3 h. Under these conditions, the mole ratio of N-dansyl-4-aminocinnamate/PAM 
was 710. The reaction mixture was dialyzed against 100 mL of 100 mM MES/NaOH pH 
6.0, 30 mM NaCl, 1% (v/v) ethanol and 0.001% (v/v) Triton X-100 for 4 h changing the 
dialysis buffer every hour. The reaction mixture was then concentrated by ultra-filtration to 
~100 mL. This sample was then trypsin digested and the peptide fragments were analyzed 
by reverse phase HPLC (Phenomenex Luna 5 μ C18 column, 250 mm × 4.6 mm) utilizing 
the in-line fluorescence detector and compared against a standard sample prepared in 
parallel in the absence of N-dansyl-4-aminocinnamate.
Enzyme modification was also examined using [ring-14C6]-trans-cinnamate. A 250 μL 
reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% 
(v/v) Triton X-100, 10 μg/mL bovine catalase, 1.0 μM Cu(NO3)2, 5.0 mM sodium ascorbate 
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and 3 μCi (50–60 nmol) of 14C-cinnamate was initiated by the addition of 0.24–0.70 nmol 
(18–52 μg) of PAM. Under these conditions, the mole ratio of [ring-14C6]-trans-
cinnamate/PAM ranged from 70 to 210. The reaction was allowed to incubate at 37° C for 3 
h before ultra-filtration was performed. The reaction was then washed with 200 μL of 100 
mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol and 0.001% (v/v) Triton X-100 
and ultra-filtration repeated. The underside of the filtration membrane was then washed with 
cold poly(ethylene glycol) to remove excess non-enzyme bound radio-labeled cinnamate. 
Counts per minute were then compared using a scintillation counter to a “no-PAM” control.
Modification of the PAM active site was also investigated as a possible means of cinnamate-
mediated inactivation. A 100 μL reaction containing 100 mM MES/NaOH pH 6.0, 30 mM 
NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 1.0 μM Cu(NO3)2, 5.0 mM sodium 
ascorbate and 3 mM cinnamate was initiated with 0.3 nmol (20 μg) of PAM and incubated at 
37 °C for 12 h. The enzyme was then dialyzed against 100 mM MES/NaOH pH 6.0, 30 mM 
NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100 for 4 h and the volume reduced to ~40 
mL by ultra-filtration. The enzyme sample was analyzed for covalent modification using 
LC/MS and MALDI-TOF and compared to an enzyme control that lacked cinnamate. The 
reactions were performed in duplicate and subjected to trypsin digestion. The sample and the 
no cinnamate control were digested with sequencing grade modified porcine trypsin in 50 
mM ammonium bicarbonate buffer (pH 8.2) at a PAM–trypsin ratio of 50:1. Proteolytic 
digestion was carried out overnight at 37 °C. The resulting peptide mixture were mixed with 
α-cyano-4-hydroxycinnamic acid solution (4 mg/mL in 50% (v/v) acetonitrile and 5% (v/v) 
isopropanol) in 1:1 ratio and spotted onto a blank stainless steel MALDI plate. MALDI-
TOF-MS was carried out on 4700 Proteomics Analyzer (Applied Biosystems, Carlsbad, CA) 
using reflective positive mode. The data were externally calibrated with 4700 Mass 
Standards (Applied Biosystems, Carlsbad, CA) from the manufacturer.
Molecular docking studies
Molecular docking studies were performed using the First Discovery 3.0 suite 
(www.schrodinger.com) on a dual 3.2 GHz Xeon workstation running Fedora Core 4 to 
investigate the possible binding modes of the inhibitors. The crystal structure for reduced 
PHM53 was obtained from the Protein Data Bank (http://www.rcsb.org/pdb/, 1SDW). All co-
crystallized species determined to be redundant for ligand binding were removed (nickel, 
water, glycerol and substrate). Formal charges for enzyme-bound copper ions and bond 
orders were corrected, and hydrogen atoms were added using Maestro. Further receptor 
refinements were carried out utilizing ProteinPrep from within Maestro. Investigation of 
inhibitor binding modes was performed using Glide54 and Qsite55 jointly for quantum-
polarized ligand docking. This method generates highly accurate binding modes by quantum 
mechanically calculating the partial atomic charges of the docked ligand using B3LYP/
6-31G* within the receptor and, subsequently, re-docking the ligand56,57. All default settings 
were used.
Density functional theory investigation of bond dissociation energies
The relative bond dissociation energies of Cα-H for select cinnamic acid analogs were 
calculated using Jaguar58 to reveal any correlation between these values and the inactivation 
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kinetic parameters. Density functional theory calculations were performed with the B3LYP 
hybrid exchange-correlation functional and the 6-31G* basis set. The geometries were 
optimized for all molecules in the gas phase. The Cα-H bond was then increased from 1.08 
to 3.0 Å with a step-size of 0.1 Å, while holding the molecule rigid, and single point 
energies were calculated.
Results
PAM inhibition by cinnamic acid analogs
Cinnamate and several cinnamate analogs were initially investigated as reversible PHM 
inhibitors. Cinnamate competitively inhibited the PHM-dependent consumption of O2, using 
N-acetylglycine as the oxidizable substrate, as shown in Figure 2. Steady-state inhibition 
constants for cinnamate and the cinnamate analogs are included in Table 1. The observed 
inhibition constants, KI,obs, ranged by a factor of 1000 from 10 μM for N-dansyl-4-
aminocinnamate to 10 mM for urocanic acid. The relatively tight-binding of N-dansyl-4-
aminocinnamate to PHM is consistent with earlier structure–activity studies indicating that 
peptide substrates possessing a hydrophobic amino acid in the penultimate position have the 
highest (V/K)app values59.
PHM-specific inactivation by cinnamate and cinnamate analogs
Cinnamate and the cinnamate analogs were first evaluated as PHM inactivators by the 
dilution method, a common method for determining the kinetic parameters for time-
dependent inactivators60. In agreement with the earlier report by Bradbury et al.33, we found 
cinnamate to inactivate the PHM-catalyzed consumption of O2 in the presence of N-
acetylglycine and ascorbate (Figure 3A).* The 1/kinact,obs versus 1/[cinnamate] replot was 
linear (Figure 3B)56.† In addition to cinnamate, only three other compounds, N-dansyl-4-
aminocinnamate, 4-aminocinnamate and N,N-dimethyl-4-aminocinnamate were found to 
inactivate PHM (Table 2). No deuterium isotope effect was observed on the cinnamate-
mediated inactivation as the (kinact/KI)obs value obtained using perdeuterated cinnamate was 
identical to that for cinnamate within experimental error (Table 2). The steady-state 
inhibition constant, KI,obs, for cinnamate, perdeuterated cinnamate, N-dansyl-4-
aminocinnamate, 4-aminocinnamate, and N,N-dimethyl-4-aminocinnamate (Table 1), was 
measured under conditions (relatively short-time frames) such that the rate of the PHM 
inactivation contributed little to the observed inhibition.
PHM inactivation by cinnamate (Table 2) was pseudo first order and was dependent upon 
the initial concentration of the inactivator, O2, and ascorbate (Figure 3B and Figure S3, 
Supplementary materials). In addition, tiopronin, a PHM substrate61, did protect PHM from 
inactivation by the cinnamate-mediated inactivation (Figure S4, Supplementary materials).
*A reviewer noted that the no cinnamate control in Figure 3(A) exhibited loss of activity. A repeat of the experiment to eliminate the 
activity loss in the no cinnamate control is difficult to accomplish because PHM exhibits a loss of activity under turnover conditions, 
probably the result of reactive, reduced O2-species that from during catalysis (see reference77). The inclusion of catalase in the 
inactivation experiments serves to decrease this problem as much as possible.†The inactivation and inhibition parameters were measured at one fixed concentration of O2 and ascorbate and are, thus, reported as 
the kinact,obs, KI,obs, and (kinact/KI)obs.
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The enzyme used for our experiments was bifunctional rat PAM comprised the separate and 
catalytically active PHM and PAL domains50. Consumption of O2 in the presence of 
ascorbate and N-acetylglycine represents the reaction catalyzed by PHM; thus, inactivation 
of O2 consumption by the cinnamates only reports on the inactivation of the PHM domain of 
bifunctional PAM. The cinnamate and a number of cinnamate analogs were tested as PAL 
inactivators to investigate whether PAM inactivation was specific to the PHM domain. The 
data indicate that PAL is unaffected by the various cinnamates tested and retained 100% 
activity when compared to the control reaction (Figure S5, Supplementary materials). 
Extensive dialysis of bifunctional PAM incubated with cinnamate yielded inactive enzyme 
unable to catalyze the production of glyoxylate from hippuric acid. All attempts to generate 
cinnamate-labeled enzyme were unsuccessful. MALDI-TOF analysis of cinnamate-
inactivated PAM showed no differences between the treated enzyme and the untreated 
control (Figure 4). Incubation of PAM with 14C-cinnamate in the presence of O2 and 
ascorbate yielded unlabeled protein, again devoid of PHM activity. Similarly, the incubation 
of bifunctional PAM with N-dansyl-4-aminocinnamate, in the presence of O2 and ascorbate, 
yielded enzyme devoid of PHM activity and also lacking any fluorescent label.
Key to fully understanding the impact of our labeling experiments is (a) the limit of 
detection of fluorescently labeled enzyme potentially generated by inactivation with N-
dansyl-4-aminocinnamate and (b) the limit of detection of 14C-labeled enzyme potentially 
generated by inactivation with 14C-cinnamate. Our level of detection of N-dansyl-4-
aminocinnamate is 20 pmol. We used 700 pmol of enzyme in our experiments to identify 
fluorescently labeled peptides from PHM inactivated with N-dansyl-4-aminocinnamate. We 
applied the tryptic digest of the N-dansyl-4-aminocinnamate inactivated PHM directly to the 
RP-HPLC column to identify any labeled peptides using our in-line fluorescent detector and 
no fluorescently labeled peptides were found. Assuming that our peptide losses are low and 
that a 1:1 cinnamate–PHM adduct forms, we would expect ~700 pmol of fluorescently 
labeled peptide, which is ~35-fold above our level of detection. These experiments show that 
labeled PHM cannot be a major product of the N-dansyl-4-aminocinnamate inactivation 
chemistry. However, a very low extent of labeling, an <0.05:1 cinnamate–PHM adduct, 
would be below our level of detection. The background level for the 14C labeling experiment 
was 20–30 cpm. We incubated 0.24–0.70 nmol of PHM with 50–60 nmol of [ring-14C6]-
cinnamate, removed the unreacted 14C-cinnamate after the inactivation reaction by 
ultrafiltration, and found no 14C-label in PHM above background. Again, assuming a low 
loss of PHM and formation of a 1:1 14C-cinnamate–PHM adduct, we expected to generate 
0.24–0.70 nmol of 14C-labeled PHM possessing 10–40 nCi of radioactivity based on specific 
radioactivity of the 14C-cinnamate (50–60 mCi/mmol). With a quenching efficiency of 60–
80% for 14C, we would have found 14C-labeled PHM in the range of 13 000–70 000 cpm – 
far above background. Only a very low extent of 14C-labeling, an <0.001:1 cinnamate–PHM 
adduct, would be below our level of detection. The most reasonable conclusion based on our 
inability to find labeled PHM upon the inactivation with N-dansyl-4-aminocinnamate or 
[ring-14C6]-cinnamate is that no labeled enzyme is produced. A result consistent with our 
analysis of inactivated PHM by mass spectrometry and that obtained for the incubation of 
PHM with 3H-PBA37.
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Computational chemistry and modeling
In silico docking of cinnamate and the cinnamate analogs indicated that all bind in the PHM 
active site consistent with the competitive inhibition observed for cinnamate (Figure 2). The 
docking pose for cinnamate is shown in Figure 5(A) and the position of cinnamate in the 
PHM active site relative to bound substrate is shown in Figure 5(B). All of the compounds 
form a salt bridge between the carboxy terminus and the guanidino group of R240 similar to 
that observed for the glycine-extended substrates53,62. This interaction aligns the Cα-H in 
close proximity to CuM, one of the two copper atoms bound to PHM53,62. However, the lack 
of glycyl amide hydrogen bonding with the N316 coupled with the relatively small size of 
the compounds prevents interaction with the nearby hydrophobic pocket, suggesting greater 
mobility when compared to glycine-extended peptide substrates.
Discussion
Structure–activity data
Cinnamate is structurally related to two PHM substrates, N-cinnamoylglycine and N-
hydrocinnamoylglycine24, and two PHM inactivators, PBA and trans-
benzoylacrylate25,34,36,37. These compounds bind to PHM with higher affinity than 
cinnamate (KI = 4 mM): KM,hydrocinnamoylglycine = 0.9 mM, KM,cinnamoylglycine = 0.2 mM, 
KI,PBA = 0.05 mM and KI,benzoylacrylate = 0.2 mM, at least to the extent that KM and KI 
values reflect relative binding affinities to PHM. Our modeling results indicate that the 
carboxylate moiety of cinnamate interacts with R240 in the PHM active site (Figure 5), as 
was demonstrated for the C-terminus of the peptide substrates62. The PHM active site 
possesses a hydrophobic pocket53,63 and our modeling results indicate that the phenyl 
moiety of cinnamate cannot reach from R240 to this hydrophobic pocket (Figure 5A). The 
presence of a longer spacer between the carboxylate moiety and the phenyl ring, like that 
found in N-cinnamoylglycine, N-hydrocinnamoylglycine, PBA, and trans-benzoylacrylate, 
enables the phenyl moiety to interact with the hydrophobic pocket within the PHM active 
site and, probably, is the main reason these four compounds are bound to PHM with higher 
affinity than cinnamate (Table 1). The relatively tight binding of N-dansyl-4-
aminocinnamate to PHM may also result from the interaction of N,N-dimethyl-1-
naphthylamine moiety of the dansyl group with the hydrophobic pocket of PHM. The small 
difference in the KI values of cinnamate and phenylpropiolic acid is likely a result of the 
differential positioning of the phenyl ring within the PHM active site. Cinnamate analogs 
with a replacement of the phenyl ring with either a pyridine ring (3-(3-pyridyl)acrylate) or 
an imidazole ring (urocanate) bind to PHM with lower affinity. The pyridine and imidazole 
rings must interact less favorably with amino acids within the PHM active site, leading to 
higher KI values for 3-(3-pyridyl)acrylate and urocanate relative to cinnamate.
Decoration of the phenyl ring of cinnamate with substituent groups results in changes in the 
affinity of PHM for the cinnamate derivative. 2-Trifluoromethyl-, 3,4-methylenedioxy-, 4-
amino-, and 4-nitro-cinnamate all bind to PHM with greater affinity than cinnamate and 
N,N-dimethyl-4-aminocinnamate binds to PHM with approximately the same affinity as 
cinnamate (Table 1). The differences in PHM affinity observed for this set of compounds 
must be related to differences in interactions between the substituent group decorating the 
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phenyl ring and active site amino acid(s). More definitive SAR results are not possible given 
the limited set of readily available ring-substituted cinnamates.
Cinnamate-mediated inactivation
Cinnamate, trans-benzoylacrylate, and PBA are not the only olefinic compounds known to 
inactivate PHM. Other olefinic inactivators of PHM include monoethyl fumarate25, 
styrylthioa-cetate38, 2- and 3-alkenoates32, vinylglycine32, 3-substituted acrylates32, 
substituted 4-oxo-2-hexenoates30, and D-Phe-L-Phe-L-vinylglycine64. Other 
monooxygenases, P450 and dopamine β-monooxygenase (DβM, structurally and 
mechanistically related to PHM), are inactivated by olefins65–68. Most of these olefinic 
inactivators exhibit characteristics of suicide substrates: the inactivation only occurs during 
enzyme turnover and substrates or competitive inhibitors protect the monooxygenases 
against inactivation. In addition, olefinic inactivation of PHM, DβM, and P450 is not 
mediated by the initial formation of the corresponding epoxide37,65,67. The inactivation of 
DβM and P450 leads to both the generation of olefin-derived oxidation products and to the 
labeling of the inactivated enzyme. Padgette et al.67 reported a partition ratio, kcat/kinact, of 
900 for inactivation of DβM with phenyl(aminomethyl)ethane and found that inactivation 
with [3H]-phenyl(aminomethyl)ethane yields 3H-labeled DbM. The inactivation of P450 with 
2-isopropyl-4-pentenamide exhibited a partition ratio of 200–300 and led to the alkylation of 
the enzyme-bound heme66. The olefinic inactivation of DβM and P450 was proposed to 
result from the formation of an olefin-derived radical intermediate66,67.
The chemistry for the inactivation of PHM by the cinnamates must be different. Incubation 
of PHM with PBA results in both O2 consumption and the generation of oxidized products, 
2- and 4-hydroxy-4-phenyl-3-butenoate, with a partition ratio of 85–9037. None of the 
compounds tested within this study showed any O2 consumption (above background) when 
screened for activity even though inactivation was O2- and ascorbate-dependent (Figure S3, 
Supplementary materials). A low background rate of O2 consumption is observed for PHM 
in the absence of an oxidizable substrate resulting from the presence of Cu(II) and ascorbate 
in an aerobic solution69. Incubation of N-dansyl-4-aminocinnamate with PHM in the 
presence of ascorbate and O2 does not result in any change in C18-reverse phase HPLC 
retention time for N-dansyl-4-aminocinnamate; additional evidence that the cinnamates are 
not PHM substrates. Finally, the lack of a deuterium kinetic isotope effect when using 
perdeuterated cinnamate as an inactivator on either kinact,obs or (kinact/KI)obs indicates that 
cinnamate-mediated inactivation of PHM does not involve rate-determining C–H bond 
cleavage.
Incubation of PHM with either [14C]-cinnamate or N-dansyl-4-aminocinnamate yielded 
inactive enzyme that was not labeled. Our comparison of trypsin-digested cinnamate-
inactivated enzyme to control (untreated) enzyme by MALDI-TOF showed no differences 
between the samples. This suggests that inactivated PHM was not covalently decorated by 
an unlabeled fragment from either of these olefins. In other words, upon inactivation, the 
phenyl ring of [14C]-cinnamate or N-dansyl-4-aminocinnamate was not lost in some manner 
yielding modified PHM without incorporation of the 14C or the dansyl group. Despite the 
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lack of labeling upon inactivation, our modeling and tiopronin protection studies indicate 
that the cinnamates are binding at the PHM active site.
The relatively low (kinact/KI)obs, values for cinnamate and the cinnamate analogs indicate 
that these compounds are more likely to dissociate from the PHM–inactivtor complex than 
inactivate PHM (Table 2). A comparison of the inactivation kinetic parameters (Table 2) to 
the relative Cα–H bond dissociation energies (Table 3) illustrates that there is no clear 
correlation between these values. For example, the Cα–H bond dissociation energy of N-
dansyl-4-aminocinnamate is approximately 2 kcal/mol higher than that of cinnamate, yet 
(kinact/KI)obs value for N-dansyl-4-aminocinnamate is ~500-fold higher than the (kinact/
KI)obs value for cinnamate. The major difference in the (kinact/KI)obs ratios between N-
dansyl-4-aminocinnamate and cinnamate stems from the contribution of binding affinity of 
each to PHM: KI,obs = 4 mM for cinnamate and 10 μM for N-dansyl-4-aminocinnamate. In 
sum, our data suggest that PHM-mediated inactivation by the cinnamate and the cinnamate 
analogs does not result from Cα–H bond cleavage: (a) no O2 consumption was observed 
when PHM was incubated with cinnamate in the presence of ascorbate and O2, (b) no 
evidence that an oxidized cinnamate is generated by incubation with PHM under turnover 
conditions, (c) no clear correlation between the inactivation kinetics and the Cα–H bond 
dissociation energies, (d) no kinetic isotope effect for the inactivation of PHM with 
perdeuterated cinnamate and (e) no labeled protein found when PHM was inactivated with 
[14C]-cinnamate or N-dansyl-4-aminocinnamate. Any mechanism that accounts for the 
cinnamate-mediated inactivation must be consistent with the data showing that inactive 
PHM has not been modified in an irreversible fashion, that cinnamate is not a PHM 
substrate, and that inactivation requires that PHM exist in a catalytically active state.
Like the chemistry proposed for the olefinic inactivation of DβM and P450, it has been 
suggested that olefinic inactivation of PHM results from the formation of a non-epoxide 
oxidized species, likely an olefin-derived radical25,33,35–38,64. This hypothesis is reasonable 
given that inactivation is turnover-dependent and that the PHM-catalyzed hydroxylation 
reaction likely proceeds through a substrate-based radical39–42. However, this proposed 
chemistry is inconsistent with our data and is thermodynamically challenging. The 
formation of a vinyl radical from cinnamate is ~80 kJ/mol higher than formation of an 
allylic radical from PBA70. It is not clear that any of the reduced oxygen species proposed to 
form during PHM catalysis are of sufficient strength to generate a vinyl radical from 
cinnamate.
We propose that inactivation of PHM occurs via the Michael addition of an active site 
nucleophile to cinnamate (Figure 6). α,β-Unsaturated carbonyls are known Michael 
acceptors71 and this chemistry is reversible, meaning that the covalently bound cinnamate 
could have been lost during the procedures used to evaluate inactive PHM. This would 
account for PHM being unlabeled after inactivation by either [14C]-cinnamate or N-
dansyl-4-aminocinnamate. The tiopronin protection studies and our modeling results 
indicate that the cinnamates bind in the active site. Potential active site nucleophiles that 
could serve as Michael donors include Lys-134, Glu-313, and Tyr-31836,53,62,72. Although 
methionine is a weak Michael donor, the potential reaction between either of the two 
important active site methionine residues, Met-109 or Met-31453,62,73, and the olefin might 
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explain olefinic inactivation of PHM. A Met-olefin Michael adduct would be readily 
reversible; thus, accounting for the lack of PHM labeling by [14C]-cinnamate or N-dansyl-4-
aminocinnamate. Formation of a reversible Michael adduct between an active site 
nucleophile and cinnamate is consistent with the lack of a kinetic isotope effect on kinact,obs 
because α-secondary deuterium effects are small (~20%, see reference74) and the lack of 
significant substituent effects on kinact,obs because electron-donating or electron-withdrawing 
groups at the para-position of cinnamate would have only a small effect on the 
electropositive nature of the cinnamoyl β-carbon. The β-carbon of cinnamate is the most 
electropositive and is the carbon atom most susceptible to nucleophilic attack.
While the reversible Michael addition of an active site nucleophile to cinnamate is one 
plausible mechanism to explain PHM inactivation, two questions remain. Why does 
cinnamate inactivation require turnover conditions and why does cinnamate-inactivated 
PHM remain inactive? Studies of the kinetic mechanism show that the O2 and the oxidizable 
substrate only bind after the reduction of enzyme-bound 2Cu(II) to 2Cu(I) by ascorbate75. 
We found that O2 binds after hippurate or benzyaldehyde iminooxy acetate76 rendering the 
O2-requirement for cinnamate inactivation perplexing. Either the order of binding for 
cinnamate is different, requiring O2 to bind to reduced PHM before cinnamate can bind, or 
O2 binding to the reduced PHM–cinnamate complex results in a subtle rearrangement in the 
active site to facilitate cinnamate attack by the active site nucleophile. The lack of 
reactivation of cinnamate-inactivated PHM would result from a relatively slow off-rate from 
native PHM. Thus, dialysis or dilution of the cinnamate-inactivated PHM would not show a 
significant regain in activity, consistent with our data. However, loss of the PHM native 
structure by denaturation or proteolysis would significantly increase the off-rate for 
cinnamate accounting for the lack of label in denaturated PHM after inactivation with 
either 14C-cinnamate or N-dansyl-4-aminocinnamate. Further complicating these 
experiments is the loss of PHM activity under turnover conditions77 meaning that 
reactivation of cinnamate-inactivated PHM under non-denaturing conditions cannot attain 
100% of the original activity.
Another potential explanation for PHM inactivation is the cinnamate-dependent removal of 
copper from the enzyme. Copper-free PHM is catalytically inactive53,62,78. Cinnamates are 
known to form complexes with both Cu(I)79,80 and Cu(II)81 and copper removal/chelation 
has been attributed to specific PHM61 and DβM inhibitors68. PHM inactivation requires 
turnover; thus, inactivation of PHM by cinnamate could result from the formation of a 
relatively high affinity cinnamate–Cu(I) complex. Our data are inconsistent with the simple 
removal of the copper from PHM to yield inactive apo-enzyme because this mode of 
inactivation would be reversible78. The time-dependence in the cinnamate inactivation could 
result in the slow accumulation of a tight-binding E–2Cu(I)–cinnamate complex. The 
cinnamate would have to bind to PHM–2Cu(I) with sufficient affinity to explain the 
irreversibility of the inactivation. PHM denaturation would result in release of the cinnamate 
accounting for the lack of enzyme labeling with either [14C]-cinnamate or N-dansyl-4-
aminocinnamate. Again, the O2-dependence of the cinnamate-mediated activation is 
problematic. Either cinnamate only binds to the E–2Cu(I)–O2 complex to form an E–
2Cu(I)–O2–cinnamate complex or O2 binding results in a subtle conformational change that 
facilitates the formation of the a E–2Cu(I)–O2–cinnamate complex. It is entirely possible 
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that the cinnamate-mediated inactivation of PHM results from a combination of both the 
formation of a Michael adduct between an active site nucleophile and cinnamate and the 
formation of tight enzyme-bound Cu(I)–cinnamate complex. Alternatively, Michael addition 
of an active site nucleophile could also subtly alter the PHM structure to enable the 
formation of a tight enzyme-bound Cu(I)–cinnamate complex that decays slowly relative to 
the retro-Michael reaction.
The Michael addition of an active site nucleophile to an unsaturated carbonyl compound 
might also account for the inactivation of PHM by the olefinic inactivators. The inactivation 
by PBA is more complex because, in contrast to the other olefinic inactivators, PBA can 
serve as a PHM substrate. Yet, PHM is not labeled by PBA37. We propose that the PBA-
mediated inactivation of PHM occurs by more than one process. Inactivation by PBA could 
occur via Michael addition/Cu(I) chelation, like the chemistry we have outlined above, and 
via a reaction between an active site amino acid and PBA-derived radical35–37. PHM 
inactivation by a PBA-derived radical would lead, most likely, to a covalent bond between 
PBA and the enzyme. Hence, inactivation by [3H]-PBA should yield [3H]-enzyme, which 
was not found. Based on this result, we suggest that Michael addition/Cu(I) chelation is the 
predominant inactivation chemistry and that inactivation via a PBA-derived radical only 
accounts for a small percentage of the inactivation yielding levels of labeled enzyme that 
were below the level of detection.
In conclusion, we have demonstrated that cinnamate and other cinnamate analogs are 
capable of PHM inactivation. The most likely explanation for the inactivation of PHM 
mediated by the cinnamates is probably the result of the reversible Michael addition of an 
active site nucleophile at the α,β-unsaturated carbonyl of the cinnamates. The slow 
accumulation of a tight and inactive PHM–2Cu(I)–cinnamate–O2 complex could also 
contribute to the net inactivation of PHM. Similar chemistry may account for the 
inactivation of PHM by other olefins. The development of a drug possessing an α,β-
unsaturated carbonyl should be evaluated as a PHM inactivator, an issue of particular 
concern given the importance of PHM in α-amidated peptide hormone biosynthesis. Also, 
these findings could prove therapeutically relevant as PHM dysfunction is correlated to a 
number of human diseases17–22, meaning that PHM could be a target for the development of 
novel olefinic-based drugs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
The reactions catalyzed by PHM and PAL (A), the cinnamate-derived vinyl radical (B) and 
the 4-phenyl-3-buteneoate-derived allylic radical (C). Bifunctional PAM is compromised of 
separate monofunctional enzymes, PHM and PAL. In vivo, the substrate for PHM and PAL 
is a C-terminal glycine extended peptide (R = a peptide) to generate an α-amidated peptide.
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Figure 2. 
Inhibition of PHM by cinnamic acid. Assays were performed as described in “Methods” 
section for the initial rate determination. The points are initial rates and the lines were 
computer fit using SigmaPlot 9.0. Initial rates of O2 consumption were measured for ≤3 min, 
during which the inactivation mediated by cinnamate makes a neglible contribution to the 
observed inhibition.
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Figure 3. 
Inactivation of PHM by cinnamic acid. (A) PHM was incubated at 37 °C in the presence of 
the indicated concentration of cinnamate as described in the “Methods” section. At the 
indicated times, an aliquot was removed and assayed for residual O2 consumption activity. 
Lines are linear regression fits to the equation: log[(vt/v0)] = (−kobs/2.303)t + C, where v0 is 
the average initial rate of O2 consumption in the absence of cinnamate, vt is the initial O2 
consumption rate at time = t, and C is a constant which should be within experimental error 
of 2.0. The error bars represent the standard deviation of the duplicate measurements. (B) A 
reciprocal replot of the inactivation data from panel A.
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Figure 4. 
MALDI-TOF overlay of trypsin-digested active and cinnamate-inactivated PHM. The 
catalytically active control is shown in blue, while the inactivated PAM is shown in red. 
Inactivation was achieved through incubation with cinnamate as described in the “Methods” 
section. This figure is best viewed in color, which is only available online.
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Figure 5. 
Binding of cinnamate into the PHM active site (A) and the relative orientation of cinnamate 
to bound substrate (N-α-acetyl-3,5-diiodotyrosylglycine, IYT) in PHM (B). The orientation 
of both the IYT (blue) and cinnamate (red) ligands is superimposed to compare recognized 
electrostatic (Arg-240) and hydrophobic (orange mesh) interactions near the CuM domain 
associated with productive ligand binding53,62. PHM contains two bound copper atoms, 
CuM and CuH53.
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Figure 6. 
Proposed mechanism for the cinnamate-mediated inactivation of PHM. E-Nu represents an 
active site nucleophile, possibilities include Lys-134, Glu-313, Tyr-318 Met-109 or Met-314.
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Table 1
KI,obs values for the inhibition of PHM by cinnamate and the cinnamate analogsa.
Name Structure KI,obs (mM)
Cinnamic acid 4 ± 0.2
Perdeuterated cinnamic acid 4 ± 0.3
N-Dansyl-4-aminocinnamic acid 0.01 ± 0.001
2-Trifluoromethylcinnamic acid 0.2 ± 0.02
3,4-Methylenedioxycinnamic acid 0.3 ± 0.04
4-Aminocinnamic acid 0.5 ± 0.06
4-Nitrocinnamic acid 0.6 ± 0.04
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Name Structure KI,obs (mM)
Phenylpropiolic acid 2 ± 0.3
N,N-Dimethyl-4-aminocinnamic acid 3 ± 0.5
3-(3-Pyridyl)acrylic acid 6 ± 0.6
Urocanic acid (1 ± 0.2) × 101
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Table 2
Values for kinact,obs and (kinact/KI)obs for cinnamate and selected cinnamate analogs.
Compound kinact,obs (min−1) (kinact/KI)obs (mM−1 min−1)
Cinnamic acid 0.2 ± 0.02 0.04 ± 0.006
N,N-Dimethyl-4-aminocinnamic acid 0.08 ± 0.01  0.03 ± 0.005
4-Aminocinnamic acid 0.03 ± 0.005 0.06 ± 0.01  
N-Dansyl-4-aminocinnamic acid 0.2 ± 0.03 (2 ± 0.3) × 101
Perdeuterated Cinnamic acid 0.2 ± 0.01 0.04 ± 0.004
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Table 3
Relative bond dissociation energies calculated for selected PHM inhibitors or inactivators.
Name kcal/mol
Cinnamic acid 0
N-Dansyl-4-aminocinnamic acid 2
4-Aminocinnamic acid 9
4-Nitrocinnamic acid 13
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